Zacks: Analysts Expect Miragen Therapeutics Inc (NASDAQ:MGEN) Will Post Quarterly Sales of $970,000.00

Wall Street brokerages expect that Miragen Therapeutics Inc (NASDAQ:MGEN) will post $970,000.00 in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Miragen Therapeutics’ earnings. The highest sales estimate is $1.50 million and the lowest is $700,000.00. Miragen Therapeutics posted sales of $480,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 102.1%. The company is expected to announce its next earnings results on Wednesday, March 11th.

On average, analysts expect that Miragen Therapeutics will report full year sales of $4.32 million for the current financial year, with estimates ranging from $3.60 million to $5.10 million. For the next year, analysts anticipate that the business will report sales of $3.27 million, with estimates ranging from $1.00 million to $6.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Miragen Therapeutics.

Miragen Therapeutics (NASDAQ:MGEN) last issued its earnings results on Thursday, November 7th. The medical research company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.67 million. Miragen Therapeutics had a negative return on equity of 113.02% and a negative net margin of 1,037.02%.

MGEN has been the subject of a number of recent research reports. Zacks Investment Research cut shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $3.00 price target on shares of Miragen Therapeutics in a research report on Monday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $11.56.

Several hedge funds have recently added to or reduced their stakes in MGEN. A.R.T. Advisors LLC acquired a new stake in Miragen Therapeutics during the second quarter worth $28,000. Citadel Advisors LLC acquired a new position in Miragen Therapeutics during the 2nd quarter worth approximately $57,000. JPMorgan Chase & Co. grew its holdings in Miragen Therapeutics by 10.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 359,243 shares of the medical research company’s stock worth $794,000 after acquiring an additional 33,557 shares in the last quarter. Invesco Ltd. bought a new position in Miragen Therapeutics during the 2nd quarter worth $71,000. Finally, Jane Street Group LLC bought a new position in Miragen Therapeutics in the 2nd quarter valued at about $159,000. 34.20% of the stock is currently owned by hedge funds and other institutional investors.

MGEN stock traded down $0.05 during trading on Friday, hitting $0.69. The stock had a trading volume of 249,855 shares, compared to its average volume of 223,709. Miragen Therapeutics has a twelve month low of $0.57 and a twelve month high of $4.96. The stock has a market capitalization of $25.43 million, a P/E ratio of -0.62 and a beta of 1.47. The company’s 50-day moving average price is $0.74 and its two-hundred day moving average price is $1.47. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.68 and a quick ratio of 3.68.

Miragen Therapeutics Company Profile

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.

Featured Article: Market Timing – The Benefits and the Danger

Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit